Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its technology—a proprietary on-demand 12-lead ECG patch—in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.
The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG while the patient is at home or on the go could provide clinicians with critical data to detect ischemia earlier, potentially preventing heart attacks and saving lives.”
The pilot study will assess the patch's ability to capture high-quality ECG signals comparable to standard 12-lead ECGs used in clinical settings. If successful, the technology could enable continuous monitoring of patients with known or suspected coronary artery disease, allowing for timely intervention when ischemic events occur. The implications are significant: ambulatory ECG monitors currently lack ischemia detection capabilities, meaning patients may miss early warning signs of reduced blood flow to the heart.
HeartBeam's approach leverages a novel electrode configuration and signal processing algorithms to derive a 12-lead ECG from a compact patch worn on the chest. This design aims to overcome limitations of existing patch monitors, which typically provide fewer leads and are used primarily for rhythm monitoring rather than ischemia detection. The company believes that enabling on-demand 12-lead recordings could expand the clinical utility of ambulatory monitoring and reduce the need for in-hospital stress tests or prolonged observation.
The market opportunity is substantial. The long-term continuous monitor and MCT market is estimated at $2 billion, driven by an aging population and increasing prevalence of cardiac conditions. A patch capable of detecting ischemia could capture a significant share of this market by addressing an unmet clinical need. HeartBeam's technology may also appeal to healthcare systems seeking to reduce costs associated with emergency department visits and hospital admissions for chest pain evaluation.
For more information about HeartBeam and its technology, visit the company’s newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially. Investors should consider the risk factors discussed in HeartBeam's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. HeartBeam undertakes no obligation to update these forward-looking statements except as required by law.
